TY  - JOUR
SN  - 2045-2322
VL  - 13
JF  - SCIENTIFIC REPORTS
EP  - 11
AV  - public
ID  - publicatio28568
Y1  - 2023///
UR  - https://doi.org/10.1038/s41598-023-44103-9
IS  - 1
TI  - Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice : results of a multicentric, retrospective study
N2  - Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials include selected patient cohorts, and thus do not necessarily represent real-world population outcomes. In this multicentric, retrospective study, we investigated real-world data to assess the effectiveness of pembrolizumab and atezolizumab and to evaluate the prognostic value of routinely available clinicopathological and laboratory parameters. Clinical and follow-up data from mUC patients who received ICIs (01/2017-12/2021) were evaluated. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and duration of response (DOR) were used as endpoints. Patients' (n = 210, n = 76 atezolizumab and 134 pembrolizumab) median OS and PFS were 13.6 and 5.9 months, respectively. Impaired ECOG-PS, the presence of visceral, liver or bone metastases, and hemoglobin levels were independently associated with poor OS and DCR. Furthermore, Bellmunt risk factors and the enhanced Bellmunt-CRP score were shown to be prognostic for OS, PFS and DCR. In conclusion, ICIs are effective treatments for a broad range of mUC patients. Our results confirmed the prognostic value of numerous risk factors and showed that Bellmunt risk scores can further be improved when adding CRP to the model.
A1  -  Váradi Melinda
A1  -  Kordáné Horváth Orsolya
A1  -  Módos Orsolya
A1  -  Fazekas Tamás
A1  -  Grunewald Camilla M
A1  -  Niegisch Günter
A1  -  Krafft Ulrich
A1  -  Grünwald Viktor
A1  -  Hadaschik Boris
A1  -  Olah Csilla
A1  -  Maráz Anikó
A1  -  Furka Andrea
A1  -  Sz?cs Miklós
A1  -  Nyirády Péter
A1  -  Szarvas Tibor
ER  -